Rapport Therapeutics Inc. Announces $250 Million Public Offering of Common Stock
Reuters
Yesterday
Rapport <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Announces $250 Million Public Offering of Common Stock
Rapport Therapeutics Inc., a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced a public offering of $250 million in common stock. The offering, which is subject to market and other conditions, will be underwritten by Goldman Sachs & Co. LLC, Jefferies, TD Cowen, and Stifel, acting as joint book-running managers. Rapport also plans to grant underwriters a 30-day option to purchase an additional $37.5 million in shares at the public offering price, excluding underwriting discounts and commissions. The offering will be conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9525319-en) on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.